[go: up one dir, main page]

ZA966287B - Avirulent herpetic viruses useful as tumoricidal agents and vaccines. - Google Patents

Avirulent herpetic viruses useful as tumoricidal agents and vaccines.

Info

Publication number
ZA966287B
ZA966287B ZA9606287A ZA966287A ZA966287B ZA 966287 B ZA966287 B ZA 966287B ZA 9606287 A ZA9606287 A ZA 9606287A ZA 966287 A ZA966287 A ZA 966287A ZA 966287 B ZA966287 B ZA 966287B
Authority
ZA
South Africa
Prior art keywords
viruses
neoplastic cells
herpetic
tumoricidal
avirulent
Prior art date
Application number
ZA9606287A
Inventor
Ian J Mohr
Yakov Gluzman
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA966287B publication Critical patent/ZA966287B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Isolated tumoricidal herpetic viruses, in particular neurotrophic herpes viruses, T-lymphotrophic viruses, and B-lymphotrophic viruses, which are avirulent and capable of selectively replicating in and destroying neoplastic cells, and pharmaceutical compositions, vaccines, and methods of destroying neoplastic cells employing the isolated tumoricidal herpetic viruses are described. A method of isolating tumoricidal herpetic viruses by sequentially passaging attenuated, avirulent herpetic viruses on neoplastic cells which fail to support replication of the herpetic viruses and isolating the viruses which grow on the neoplastic cells is also described. Herpes simplex virus mutants having a genome from which the gamma 34.5 genes have been deleted and which require at least one additional mutation to produce a non-neurovirulent herpes simplex virus which selectively replicates in and destroys neoplastic cells are also described.
ZA9606287A 1995-07-27 1996-07-24 Avirulent herpetic viruses useful as tumoricidal agents and vaccines. ZA966287B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US160295P 1995-07-27 1995-07-27

Publications (1)

Publication Number Publication Date
ZA966287B true ZA966287B (en) 1998-03-09

Family

ID=21696918

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606287A ZA966287B (en) 1995-07-27 1996-07-24 Avirulent herpetic viruses useful as tumoricidal agents and vaccines.

Country Status (10)

Country Link
EP (1) EP0841943B1 (en)
AT (1) ATE248604T1 (en)
AU (1) AU725557B2 (en)
CA (1) CA2227860C (en)
DE (1) DE69629819T2 (en)
DK (1) DK0841943T3 (en)
ES (1) ES2205053T3 (en)
IL (1) IL118942A (en)
WO (1) WO1997004804A1 (en)
ZA (1) ZA966287B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
MXPA02002142A (en) * 1999-08-31 2003-04-10 Gen Hospital Corp Cell specific and or tumor specific promoter retargeting of herpes gamma 34.5 gene expression.
WO2001053506A2 (en) 2000-01-21 2001-07-26 Biovex Limited Virus strains for the oncolytic treatment of cancer
CA2352439A1 (en) * 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment

Also Published As

Publication number Publication date
DK0841943T3 (en) 2003-12-08
ES2205053T3 (en) 2004-05-01
AU6713996A (en) 1997-02-26
EP0841943B1 (en) 2003-09-03
CA2227860C (en) 2011-05-24
DE69629819T2 (en) 2004-05-06
IL118942A (en) 2002-09-12
IL118942A0 (en) 1996-10-31
EP0841943A1 (en) 1998-05-20
WO1997004804A1 (en) 1997-02-13
DE69629819D1 (en) 2003-10-09
CA2227860A1 (en) 1997-02-13
AU725557B2 (en) 2000-10-12
ATE248604T1 (en) 2003-09-15

Similar Documents

Publication Publication Date Title
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
DE69121452D1 (en) Gene sequence transfer and expression in central nervous system cells with mutant herpes simplex viruses that contain deletions in virus replication genes
NZ335000A (en) Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
ES2074950A1 (en) Viral vaccine for the prevention of porcine reproductive and respiratory syndrome
FR16C0026I1 (en)
ATE73348T1 (en) THYMIDINE KINASE DELETION MUTANTS OF BOVINE HERPESVIRUS-1, VACCINES AGAINST BOVINE RHINOTRACHEITIS CONTAINING THEM, AND METHODS FOR THEIR MANUFACTURE AND USE.
PT1526172E (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
GB9017767D0 (en) Herpes simplex virus type 1 mutant
GR3033909T3 (en) Cytosine deaminase negative selection system for gene transfer techniques and therapies.
IL118942A0 (en) Avirulent herpetic viruses useful as tumericidal agents and vaccines
CA2073288A1 (en) Manipulation of gene copy number in bordetella
Litman et al. The induction of mutants of bacteriophage T2 by 5-bromouracil: IV. Kinetics of bromouracil-induced mutagenesis
EP0326127A3 (en) Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same
FR2563533B1 (en) METHOD FOR AMPLIFYING THE EXPRESSION OF A DETERMINED GENE IN SUBACTIVE BACILLUS AND STRAINS OBTAINED
WO1994000586A3 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
AU3977997A (en) Assembly-deficient herpesvirus vaccine
Loveday et al. The fate of bacteriophage φe transfecting DNA
WO1996001615A3 (en) Hepatitis a virus deletion mutants and vaccine formulations containing the same
Bridges et al. Mutagenesis in Escherichia coli V. Attempted interconversion of ochre and amber suppressors and mutational instability due to an ochre suppressor
JPS57206699A (en) Plasmid patm 3 and its preparation
WO1993018151A1 (en) Transposable element originating in bacterium of the genus brevibacterium
EP1032418A4 (en) Compact epstein-barr virus replicons
ZEIGEL et al. Characterization of Virus-like Particles Released from the Hamster: Cell Eine CHO-K1 After Treatment with 5-Bromodeoxyuridine. By KF MANLY, JF GIVENS, RL TA~ ER and
ATE46264T1 (en) THYMIDINE KINASE NEGATIVE TEMPERATURE-RESISTANT BOVINE HERPES VIRUS 1 MUTANT VACCINE AGAINST BOVINE INFECTIOUS RHINOTRACHEITIS.
CA2250714A1 (en) Animal cells and processes for the replication of influenza viruses